A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Tumor Biology

• Publication date

  2010-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-010-0065-1PMID 20589491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.

  2009cited by this paper
• Cholangiocarcinoma.

  2009cited by this paper
• A Critical Analysis of the Surgical Management of Early-Stage Gallbladder Cancer in the United States

  2009cited by this paper
• Factors predictive of prognosis after esophagectomy for squamous cell cancer.

  2009cited by this paper
• Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology

  2009influential reference
• Cytokines in the management of high risk or advanced breast cancer: an update and expectation.

  2009cited by this paper
• Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.

  2009cited by this paper
• Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs

  2008cited by this paper
• Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial

  2008cited by this paper
• Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.

  2008cited by this paper
• Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution.

  2008cited by this paper
• Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes

  2008cited by this paper
• Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.

  2007cited by this paper
• Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.

  2007cited by this paper
• Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).

  2007cited by this paper
• Analyzing survival curves at a fixed point in time

  2007cited by this paper
• Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells

  2007cited by this paper
• Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

  2007cited by this paper
• Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

  2007cited by this paper
• Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology.

  2006cited by this paper
• Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

  2006cited by this paper
• Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

  2006cited by this paper
• Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery

  2006cited by this paper
• Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.

  2006cited by this paper
• An Immunotherapy Schedule in Endocrine-Dependent Metastatic Breast Cancer: Correlation Between Clinical Course and Immunologic Parameters

  2005cited by this paper
• Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

  2005cited by this paper
• Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

  2005cited by this paper
• Concurrent chemoradiotherapy of twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.

  2004cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.

  2003cited by this paper
• Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group.

  2002cited by this paper
• Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal.

  2001cited by this paper
• Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases

  2001cited by this paper
• Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.

  2000cited by this paper
• A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.

  1998cited by this paper
• Resection of hepatic metastases from colorectal cancer

  1998cited by this paper
• Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

  1998cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.

  1998cited by this paper
• Hepatic resection and transplantation for peripheral cholangiocarcinoma.

  1997cited by this paper
• Liver resection for colorectal metastases.

  1997cited by this paper
• A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study.

  1997cited by this paper
• Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.

  1996cited by this paper
• Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.

  1995cited by this paper
• Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie.

  1994cited by this paper
• Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).

  1994cited by this paper
• European studies of interleukin-2 in metastatic renal cell carcinoma.

  1993cited by this paper
• Metabolism and mechanism of action of 5-fluorouracil.

  1990cited by this paper
• Resection of hepatic metastases from colorectal cancer. Biologic perspective.

  1989cited by this paper
• A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

  1989cited by this paper
• Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.

  1987cited by this paper

• Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

  2022cites this paper
• Minimal residual disease in advanced or metastatic solid cancers: the G0-G1 state and immunotherapy are key to unwinding cancer complexity.

  2020cites this paper
• Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

  2019cites this paper
• Tumour growth and immune evasion as targets for a new strategy in advanced cancer.

  2018cites this paper
• Additional 5-FU-LV significantly increases survival in gastrointestinal cancer.

  2011influential citation